Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05296304 · ClinicalTrials.gov registry record · Phase 1

A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides

A Phase 1 study of Cutaneous T Cell Lymphoma, sponsored by Memorial Sloan Kettering Cancer Center.

Recruiting
Registry status
Phase 1
Development phase
20
Enrollment target
3
Study locations

NCT05296304 is a Phase 1 study of Cutaneous T Cell Lymphoma that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 20 participants, below the 67-participant average among 23 other Cutaneous T Cell Lymphoma trials with a reported enrollment target (70% lower). The trial reports 3 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05296304, a Phase 1 study of Cutaneous T Cell Lymphoma, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.

RECRUITING
Registry status
Phase 1
Development phase
20 participants
Enrollment target
3
Study locations

Study Summary

The researchers are doing this study to test the safety of combining bexarotene with TSEB radiotherapy in people who have a common form of CTCL called mycosis fungoides (MF). Bexarotene is a form of vitamin A that activates proteins called retinoid X receptors, which may stop the growth of cancer cells and kill them. TSEB radiotherapy is a type of radiation therapy that treats the entire surface of the skin with very low doses of radiation to kill cancer cells and shrink tumors. This type of radiation does not pass through the outer layers of the skin into the tissues and organs below the skin. The study researchers think that giving bexarotene treatment at the same time as treatment with TSEB radiotherapy may be more effective against MF than either treatment given alone or in sequence (one after the other).

Conditions Studied

Cutaneous T Cell Lymphoma

Interventions

  • DRUG Bexarotene
  • RADIATION Total Skin Electron Beam (TSEB)

Study Locations (3)

New York

  • Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) - Commack
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
  • Memorial Sloan Kettering Nassau (Limited Protocol Activites) - Rockville Centre

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2022-03-16
Est. Completion 2027-03
Phase Phase 1

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05296304

The ClinicalTrials.gov registry entry for NCT05296304 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 67-participant average among 23 other Cutaneous T Cell Lymphoma trials with a reported enrollment target (70% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cutaneous T Cell Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Bexarotene is the first listed.

NCT05296304 reports 3 study locations spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT05296304 about?

NCT05296304 is a clinical study titled "A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides". The researchers are doing this study to test the safety of combining bexarotene with TSEB radiotherapy in people who have a common form of CTCL called mycosis fungoides (MF). Bexarotene is a form of vitamin A that activates proteins called retinoid X receptors, which may stop the growth of cancer c...

What is the current status of trial NCT05296304?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2022-03-16. Estimated completion is 2027-03.

What conditions does trial NCT05296304 study?

This clinical trial studies the following conditions: Cutaneous T Cell Lymphoma.

What interventions are being tested in trial NCT05296304?

The interventions under investigation include: Bexarotene (DRUG), Total Skin Electron Beam (TSEB) (RADIATION).

Who is sponsoring clinical trial NCT05296304?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05296304 being conducted?

This trial has 3 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cutaneous T Cell Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cutaneous T Cell Lymphoma

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.